Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels <0.1 mIU/l (grade 2 SHyper). Therefore, despite the absence of randomized prospective trials, there is evidence that treatment is indicated in patients older than 65 years with grade 2 SHyper to potentially avoid these serious cardiovascular events, fractures and the risk of progression to overt hyperthyroidism. Treatment could be considered in patients older than 65 years with TSH levels 0.1-0.39 mIU/l (grade 1 SHyper) because of their increased risk of atrial fibrillation, and might also be reasonable in younger (<65 years) symptomatic patients with grade 2 SHyper because of the risk of progression, especially in the presence of symptoms and/or underlying risk factors or co-morbidity. Finally, the task force concluded that there are no data to support treating SHyper in younger asymptomatic patients with grade 1 SHyper. These patients should be followed without treatment due to the low risk of progression to overt hyperthyroidism and the weaker evidence for adverse health outcomes.

Keywords:
Subclinical hyperthyroidism, Progression, Cardiovascular risk, Cognition, Bone risk, Management, Antithyroid drugs, Radioactive iodine, Surgery
1.
Surks MI, Ortiz E, Daniels GH, et al: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291:228-238.
2.
Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G: Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 2005;152:1-9.
3.
Biondi B, Cooper DS: The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008;29:76-131.
4.
Bahn RS, Burch HB, Cooper DS, et al: Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21:593-646.
5.
Cooper DS, Biondi B: Subclinical thyroid disease. Lancet 2012;379:1142-1154.
6.
Mitchell AL, Pearce SH: How should we treat patients with low serum thyrotropin concentrations? Clin Endocrinol (Oxf) 2010;72:292-296.
7.
Bülow Pedersen I, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Laurberg P: Large differences in incidences of overt hyper- and hypothyroidism associated with a small difference in iodine intake: a prospective comparative register-based population survey. J Clin Endocrinol Metab 2002;87:4462-4469.
8.
Marqusee E, Haden ST, Utiger RD: Subclinical thyrotoxicosis. Endocrinol Metab Clin North Am 1998;27:37-49.
9.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC: The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534.
10.
Hollowell JG, Staehling NW, Flanders WD, et al: Serum TSH, T(4), and thyroid antibodies in the United States population (1988-1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-499.
11.
Aghini-Lombardi F, Antonangeli L, Martino E, et al: The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab 1999;84:561-566.
12.
Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, Wemeau JL: 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J 2013;2:215-228.
13.
Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP: 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. Eur Thyroid J 2012;1:55-71.
14.
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011;57:e101-e198.
15.
Paschke R, Hegedüs L, Alexander E, Valcavi R, Papini E, Gharib H: Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat Rev Endocrinol 2011;7:354-361.
16.
Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR; Guidelines Committee, National Academy of Clinical Biochemistry: Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3-126.
17.
Figge J, Leinung M, Goodman AD, Izquierdo R, Mydosh T, Gates S, Line B, Lee DW: The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T3) toxicosis. Am J Med 1994;96:229-234.
18.
Biondi B: Natural history, diagnosis and management of subclinical thyroid dysfunction. Best Pract Res Clin Endocrinol Metab 2012;26:431-446.
19.
Cooper DS, Laurberg P: Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 2013;1:238-249.
20.
Harman SM, Wehmann RE, Blackman MR: Pituitary-thyroid hormone economy in healthy aging men: basal indices of thyroid function and thyrotropin responses to constant infusions of thyrotropin releasing hormone. J Clin Endocrinol Metab 1984;58:320-326.
21.
Mariotti S, Franceschi C, Cossarizza A, Pinchera A: The aging thyroid. Endocr Rev 1995;16:686-715.
22.
Surks MI, Boucai L: Age- and race-based serum thyrotropin reference limits. J Clin Endocrinol Metab 2010;95:496-502.
23.
Magri F, Muzzoni B, Cravello L, Fioravanti M, Busconi L, Camozzi D, Vignati G, Ferrari E: Thyroid function in physiological aging and in centenarians: possible relationships with some nutritional markers. Metabolism 2002;51:105-109.
24.
Mariotti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, Franceschi C, Pinchera A: Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 1993;77:1130-1134.
25.
Belin RM, Astor BC, Powe NR, Ladenson PW: Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2004;89:6077-6086.
26.
Kahaly GJ, Bartalena L, Hegedüs L: The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid 2011;21:585-591.
27.
Diana T, Kanitz M, Lehmann M, Li Y, Olivo PD, Kahaly GJ: Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies. Thyroid 2015;25:169-175.
28.
Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P: TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf) 2001;55:381-390.
29.
Hegedüs L, Bonnema SJ: Approach to management of the patient with primary or secondary intrathoracic goiter. J Clin Endocrinol Metab 2010;95:5155-5162.
30.
Abrahamsen B, Jørgensen HL, Laulund AS, Nybo M, Brix TH, Hegedüs L: Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures. The OPENTHYRO Register Cohort. J Bone Miner Res 2014;29:2040-2050.
31.
Díez JJ, Iglesias P: An analysis of the natural course of subclinical hyperthyroidism. Am J Med Sci 2009;337:225-232.
32.
Vadiveloo T, Donnan PT, Cochrane L, Leese GP: The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011;96:1-8.
33.
Rosario PW: Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol 2010;72:685-688.
34.
Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI: Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch Intern Med 2007;23:167:1533-1538.
35.
Schouten BJ, Brownlie BEW, Frampton CM, Turner JG: Subclinical thyrotoxicosis in an outpatient population - predictors of outcome. Clin Endocrinol 2001;74:257-261.
36.
Rosario PW: The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clin Endocrinol 2008;68:491-492.
37.
Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE: Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol 2012;77:146-151.
38.
Woeber KA: Observations concerning the natural history of subclinical hyperthyroidism. Thyroid 2005;15:687-691.
39.
Wiersinga WM: Subclinical hyperthyroidism and hypothyroidism. I. Prevalence and clinical relevance. Neth J Med 1995;46:197-204.
40.
Effraimidis G, Strieder TG, Tijssen JG, Wiersinga WM: Natural history of the transition from euthyroidism to overt autoimmune hypo- or hyperthyroidism: a prospective study. Eur J Endocrinol 2011;164:107-113.
41.
Stanbury JB, Ermans AE, Bourdoux P, et al: Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 1998;8:83-100.
42.
Elte JW, Bussemaker JK, Haak A: The natural history of euthyroid multinodular goitre. Postgrad Med J 1990;66:186-190.
43.
Wiener JD, de Vries AA: On the natural history of Plummer's disease. Clin Nucl Med 1979;4:181-190.
44.
Belfiore A, Sava L, Runello F, Tomaselli L, Vigneri R: Solitary autonomously functioning thyroid nodules and iodine deficiency. J Clin Endocrinol Metab 1996;56:283-287.
45.
Biondi B, Palmieri EA, Fazio S, et al: Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 2003;85:4701-4705.
46.
Sgarbi JA, Villaca F, Garbeline B, Villar HE, Romaldini JH: The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism on clinical and heart abnormalities. J Clin Endocrinol Metab 2003;88:1672-1677.
47.
Biondi B, Fazio S, Carella C, et al: Control of adrenergic overactivity by β-blockade improves quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1994;78:1028-1033.
48.
Gullu S, Altuntas F, Dincer I, Erol C, Kamel N: Effects of TSH suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunction. Eur J Endocrinol 2004;150:655-661.
49.
Stott DJ, McLellan AR, Finlayson J, Chu P, Alexander WD: Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at increased risk of developing overt hyperthyroidism. Q J Med 1991;78:77-84.
50.
Boelaert K, Torlinska B, Holder RL, Franklyn JA: Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010;95:2715-2726.
51.
Roberts LM, Pattison H, Roalfe A, Franklyn J, Wilson S, Hobbs FD, Parle JV: Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med 2006;145:573-581.
52.
Sawin CT, Geller A, Wolf PA, et al: Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-1252.
53.
Cappola AR, Fried LP, Arnold AM, et al: Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006;295:1033-1041.
54.
Tan ZS, Beiser A, Vasan RS, et al: Thyroid function and the risk of Alzheimer disease: the Framingham Study. Arch Intern Med 2008;168:1514-1520.
55.
Döbert N, Hamscho N, Menzel C, et al: Subclinical hyperthyroidism in dementia and correlation of the metabolic index in FDG-PET. Acta Med Austriaca 2003;30:130-133.
56.
van Osch LA, Hogervorst E, Combrinck M, Smith AD: Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease. Neurology 2004;62:1967-1971.
57.
van der Cammen TJ, Mattace-Raso F, van Harskamp F, de Jager MC: Lack of association between thyroid disorders and Alzheimer's disease in older persons: a cross-sectional observational study in a geriatric outpatient population. J Am Geriatr Soc 2003;51:884.
58.
de Jong FJ, den Heijer T, Visser TJ, et al: Thyroid hormones, dementia and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 2006;91:2569-2573.
59.
Gan EH, Pearce SH: The thyroid in mind: cognitive function and low thyrotropin in older people. J Clin Endocrinol Metab 2012;97:3438-3449.
60.
Moon JH, Park YJ, Kim TH, et al: Lower-but-normal serum TSH level is associated with the development or progression of cognitive impairment including mild cognitive impairment and dementia in elderly: Korean Longitudinal Study on Health and Aging (KLoSHA). J Clin Endocrinol Metab 2014;99:424-432.
61.
Wijsman LW, de Craen AJ, Trompet S, Gussekloo J, Stott DJ, Rodondi N, Welsh P, Jukema JW, Westendorp RG, Mooijaart SP: Subclinical thyroid dysfunction and cognitive decline in old age. PLoS One 2013;8:e59199.
62.
Virgini VS, Wijsman LW, Rodondi N, Bauer DC, Kearney PM, Gussekloo J, den Elzen WP, Jukema JW, Westendorp RG, Ford I, Stott DJ, Mooijaart SP; PROSPER Study Group: Subclinical thyroid dysfunction and functional capacity among elderly. Thyroid 2014;24:208-214.
63.
Vadiveloo T, Donnan PT, Cochrane L, Leese GP: The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 2011;96:1344-1351.
64.
Biondi B, Palmieri EA, Lombardi G, Fazio S: Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab 2002;87:968-974.
65.
Biondi B, Kahaly GJ: Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 2010;6:431-443.
66.
Fazio S, Palmieri EA, Lombardi G, Biondi B: Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004;59:31-50.
67.
Kaminski G, Michalkiewicz D, Makowski K, et al: Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism. Clin Endocrinol 2011;74:501-507.
68.
Biondi B: Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur J Endocrinol 2012;167:609-618.
69.
Pearce EN, Yang Q, Benjamin EJ, Aragam J, Vasan RS: Thyroid function and left ventricular structure and function in the Framingham Heart Study. Thyroid 2010;20:369-373.
70.
Dörr M, Ittermann T, Aumann N, Obst A, Reffelmann T, Nauck M, Wallaschofski H, Felix SB, Völzke H: Subclinical hyperthyroidism is not associated with progression of cardiac mass and development of left ventricular hypertrophy in middle-aged and older subjects: results from a 5-year follow-up. Clin Endocrinol 2010;73:821-826.
71.
Collet TH, Gussekloo J, Bauer DC, et al; Thyroid Studies Collaboration: Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012;172:799-809.
72.
Auer JA, Scheibner P, Mische T, Langsteger W, Eber O, Eber B: Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 2001;142:838-842.
73.
Gammage MD, Parle JV, Holder RL, et al: Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007;167:928-934.
74.
Selmer C, Olesen JB, Hansen ML, et al: The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 2012;345:e7895.
75.
Gencer B, Collet TH, Virgini V, et al; Thyroid Studies Collaboration: Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012;126:1040-1049.
76.
Nanchen D, Gussekloo J, Westendorp RG, et al; PROSPER Group: Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012;97:852-861.
77.
Selmer C, Olesen JB, Hansen ML, et al: Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014;99:2372-2382.
78.
Squizzato A, Gerdes VE, Brandjes DP, Büller HR, Stam J: Thyroid diseases and cerebrovascular disease. Stroke 2005;36:2302-2310.
79.
Schultz M, Kistorp C, Raymond I, Dimsits J, Tuxen C, Hildebrandt P, Faber J: Cardiovascular events in thyroid disease: a population based, prospective study. Horm Metab Res 2011;43:653-659.
80.
Chaker L, Baumgartner C, Ikram MA, Dehghan A, Medici M, Visser WE, Hofman A, Rodondi N, Peeters RP, Franco OH: Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. Eur J Epidemiol 2014;29:791-800.
81.
Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA: Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001;358:861-865.
82.
Drechsler C, Schneider A, Gutjahr-Lengsfeld L, Kroiss M, Carrero JJ, Krane V, Allolio B, Wanner C, Fassnacht M: Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients. Am J Kidney Dis 2014;63:988-996.
83.
Brandt F, Green A, Hegedüs L, Brix TH: A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol 2011;165:491-497.
84.
Brandt F, Thvilum M, Almind D, et al: Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid 2013;23:408-413.
85.
Brandt F, Almind D, Christensen K, Green A, Brix TH, Hegedüs L: Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a Danish nationwide register-based cohort study of twins and singletons. J Clin Endocrinol Metab 2012;97:4123-4129.
86.
Brandt F, Thvilum M, Almind D, et al: Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One 2013;8:e66711.
87.
van de Ven AC, Netea-Maier RT, de Vegt F, Ross HA, Sweep FC, Kiemeney LA, Smit JW, Hermus AR, den Heijer M: Associations between thyroid function and mortality: the influence of age. Eur J Endocrinol 2014;171:183-191.
88.
Laulund AS, Nybo M, Brix TH, Abrahamsen B, Jørgensen HL, Hegedüs L: Duration of thyroid dysfunction correlates with all-cause mortality. The OPENTHYRO Register Cohort. PLoS One 2014;9:e110437.
89.
Völzke H, Schwahn C, Wallaschofski H, Dörr M: Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J Clin Endocrinol Metab 2007;92:2421-2429.
90.
Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R: Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2008;28:41-48.
91.
Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, Rodondi N: Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008;148:832-845.
92.
Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B: Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol 2008;159:329-341.
93.
Yang LB, Jiang DQ, Qi WB, Zhang T, Feng YL, Gao L, Zhao J: Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. Eur J Endocrinol 2012;167:75-84.
94.
Cappola AR, Arnold AM, Wulczyn K, Carlson M, Robbins J, Psaty BM: Thyroid function in the euthyroid range and adverse outcomes in older adults. J Clin Endocrinol Metab 2015;100:1088-1096.
95.
Vestergaard P, Mosekilde L: Hyperthyroidism, bone mineral, and fracture risk - a meta-analysis. Thyroid 2003;13:585-593.
96.
De Menis E, Da Rin G, Roiter I, Legovini P, Foscolo G, Conte N: Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Horm Res 1992;37:217-220.
97.
Gurlek A, Gedik O: Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999;9:539-543.
98.
Ugur-Altun B, Altun A, Arikan E, Guldiken S, Tugrul A: Relationships existing between the serum cytokine levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism. Endocr Res 2003;29:389-398.
99.
Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K: Normalization of serum thyrotropin by mean of radioiodine treatment in subclinical hyperthyroidism. Effect of bone loss in postmenopausal women. Clin Endocrinol 1998;48:285-290.
100.
Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC: Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol 1994;41:421-424.
101.
Foldes J, Tarjan G, Szathmary M, Varga F, Krasznai I, Horvath C: Bone mineral density in patients with endogenous subclinical hyperthyroidism: is the thyroid status a risk factor for osteoporosis? Clin Endocrinol 1993;39:521-527.
102.
Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y: Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000;85:4157-4161.
103.
Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R: The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromso study. Thyroid 2008;18:1147-1555.
104.
Tauchmanova L, Nuzzo V, Del Puente A, et al: Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas 2004;48:299-306.
105.
Bauer DC, Ettinger B, Nevitt MC, Stone KL; Study of Osteoporotic Fractures Research Group: Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 2001;134:561-568.
106.
Lee JS, Buzková P, Fink HA, et al: Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 2010;170:1876-1883.
107.
Abrahamsen B, Jørgensen HL, Laulund AS, Nybo M, Bauer D, Brix TH, Hegedüs L: The excess risk of major osteoporotic fractures is driven by cumulative hyperthyroid as opposed to hypothyroid time. An observational register-based time resolved cohort analysis. J Bone Miner Res 2014;29:2040-2050.
108.
Wirth CD, Blum MR, da Costa BR, Baumgartner C, Collet TH, Medici M, Peeters RP, Aujesky D, Bauer DC, Rodondi N: Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis. Ann Intern Med 2014;5;161:189-199.
109.
Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Åsvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Jüni P, Aujesky D, Rodondi N; Thyroid Studies Collaboration: Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 2015;313:2055-2065.
110.
Cooper DS: Approach to the patient with subclinical hyperthyroidism. Clin Endocrinol Metab 2007;92:3-9.
111.
Buscemi S, Verga S, Cottone S, et al: Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism. J Endocrinol Invest 2007;30:230-235.
112.
Rosario PW: Radioiodine therapy in elderly patients with subclinical hyperthyroidism due to non-voluminous nodular goiter and its effect on bone metabolism. Arq Bras Endocrinol Metabol 2013;57:144-147.
113.
Greenlund LJ, Nair KS, Brennan MD: Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocr Pract 2008;14:973-978.
114.
Laurberg P, Krejbjerg A, Andersen SL: Relapse following antithyroid drug therapy for Graves' hyperthyroidism. Curr Opin Endocrinol Diab Obes 2014;21:415-421.
115.
Cooper DS: Antithyroid drugs. N Engl J Med 2005;352:905-917.
116.
Nakamura H, Miyauchi A, Miyawaki N, Imagawa J: Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 2013;98:4776-4783.
117.
Franklyn JA, Boelaert K: Thyrotoxicosis. Lancet 2012;379:1155-1166.
118.
Bonnema SJ, Bertelesen H, Mortensen J, et al: The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999;84:3636-3641.
119.
Bonnema SJ, Hegedüs L: Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012;33:920-980.
120.
Porterfield JR Jr, Thompson GB, Farley DR, Grant CS, Richards ML: Evidence-based management of toxic multinodular goiter (Pummer's disease). World J Surg 2008;32:1278-1284.
121.
Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA: Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab 2013;98:1869-1882.
122.
Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B: Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007;10;334:514.
123.
Bartalena L: The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 2011;96:592-599.
124.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-2104.
125.
Cappola AR, Cooper D: Screening and treating subclinical thyroid disease: getting past the impasse. Ann Intern Med 2015;162:664-665.
© 2015 European Thyroid Association Published by S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.